2-(3,4-二羟基苯基)乳酸 | 22681-72-7

• 物质功能分类: 分析化学 - 对照品
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 2-(3,4-二羟基苯基)乳酸
• 中文别名: 丹参素
• 英文名称: 2-(3,4-Dihydroxyphenyl)-2-hydroxypropanoic acid
• CAS: 22681-72-7
• 化学式: C₉H₁₀O₅
• mdl: MFCD09038703
• 分子量: 198.17
• InChiKey: NDGMYGNFKSMYBB-UHFFFAOYSA-N

物化性质

• 沸点：
  480.3±40.0 °C(Predicted)
• 密度：
  1.540±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• 海关编码：
  2942000000

文献信息

• Improved biological effects of rosmarinic acid
  申请人：Nestec S.A.

  公开号：EP1917960A1

  公开（公告）日：2008-05-07

  The present invention relates to compositions comprising rosmarinic acid and/or its derivatives and to the use of a hydrolytic enzyme or of microorganism containing hydrolytic enzymes in these compositions. The invention also pertains to methods for improving the biological effects of said rosemary extracts.

  本发明涉及包含迷迭香酸和/或其衍生物的组合物，以及在这些组合物中使用水解酶或含有水解酶的微生物。本发明还涉及改善所述迷迭香提取物生物效应的方法。
• USE OF DANSHENSU, NOTOGINSENOSIDE R1 OR THEIR COMBINATION IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING DISEASES CAUSED BY MICROCIRCULATION DISORDER
  申请人：Tasly Pharmaceutical Group Co., Ltd.

  公开号：EP2497469A1

  公开（公告）日：2012-09-12

  The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.

  本发明涉及一种丹参素（DLA）、羌活皂苷R1（R1）及其复方中药产品的新用途，特别是丹参素、羌活皂苷R1及其复方中药产品对微循环障碍所致疾病的治疗和预防作用。
• TRADITIONAL CHINESE DRUG COMPRISING DANSHEN EXTRACTS AND SANQI EXTRACTS AND USE THEREOF
  申请人：Tasly Pharmaceutical Group Co., Ltd.

  公开号：EP2514418A1

  公开（公告）日：2012-10-24

  The present invention discloses a traditional Chinese drug consisting of Danshen extract and Sanqi extract, the pharmaceutical composition comprising the above traditional Chinese drug as an active component and the use thereof. The traditional Chinese drug consists of Danshen extract and Sanqi extract in a weight ratio of (2~6): (0.5~2). The invention further discloses the effect of the above traditional Chinese drug and the pharmaceutical composition comprising the above traditional Chinese drug as an active component for treating cardiac microcirculation disorder and myocardial damage induced by ischemia/reperfusion.

  本发明公开了一种由丹参提取物和三七提取物组成的中药、以上述中药为有效成分的药物组合物及其用途。该中药由丹参提取物和三七提取物组成，重量比为（2~6）：(0.5~2).本发明进一步公开了上述中药和以上述中药为活性成分的药物组合物治疗缺血再灌注引起的心脏微循环障碍和心肌损伤的效果。
• STRAIN AND METHOD FOR PRODUCING ROSMARINIC ACID
  申请人：Hongtaosim Research Institute Of Analycal Science And Technology Co., Ltd.

  公开号：EP3992298A1

  公开（公告）日：2022-05-04

  Provided are a strain and method for producing rosmarinic acid. Recombinant cells expressing 4-coumarate-CoA ligase, rosmarinic acid synthase, polyphosphate kinase 2-1 and polyphosphate kinase 2-II or combinations of the recombinant cells are constructed, and the recombinant cells or the combinations of the recombinant cells are used for catalyzing synthesis of rosmarinic acid from Danshensu and caffeic acid.

  本发明提供了一种生产迷迭香酸的菌株和方法。构建了表达 4-香豆酸-CoA连接酶、迷迭香酸合成酶、多磷酸激酶 2-1 和多磷酸激酶 2-II 的重组细胞或重组细胞的组合，并利用重组细胞或重组细胞的组合催化丹参素和咖啡酸合成迷迭香酸。
• Rosemary in a tobacco blend
  申请人：R.J. REYNOLDS TOBACCO COMPANY

  公开号：US10226066B2

  公开（公告）日：2019-03-12

  Provided are smoking products and methods of preparing smoking products that include tobacco and a deflavored rosemary or a heat-treated rosemary. The deflavored and/or heat-treated rosemary may have been previously heated at a temperature and a time sufficient to reduce or remove flavorant components compared to the use of untreated rosemary. The heated rosemary may include one or more pentacyclic triterpenoid acids such as betulinic, betul-18-enoic, oleanolic, and ursolic acids.

  本发明提供了包括烟草和脱味迷迭香或热处理迷迭香的烟用产品和烟用产品的制备方法。与使用未经处理的迷迭香相比，脱味迷迭香和/或热处理迷迭香先前可能已在足以减少或去除香料成分的温度和时间下进行过加热。加热后的迷迭香可包括一种或多种五环三萜酸，如白桦脂酸、白桦脂-18-烯酸、齐墩果酸和熊果酸。